Calithera Commences Mid-Stage Study Of DLBCL Candidate
June 23, 2022 at 17:35 PM EDT
Calithera Biosciences, Inc. (NASDAQ: CALA) initiates dosing first patient in the phase 2 clinical trial evaluating its spleen tyrosine ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.